[Correspondence] Dengvaxia: age as surrogate for serostatus
Since April, 2016, Dengvaxia —a dengue vaccine produced by Sanofi Pasteur (Lyon, France)—has been licensed for use in 19 countries. Dengvaxia was recommended by the WHO Strategic Advisory Group of Experts (SAGE) on immunisation to be used in regions with high endemicity, as defined by a prevalence of dengue antibodies of mo re than 50% in the targeted age group of people aged 9–45 years.1 We have previously discussed the risks behind this vaccine recommendation,2,3 and by analysing an age-structured model4 using the available vaccine trial data1 predicted a significant reduction in dengue virus infection-related hosp ital admissions if Dengvaxia is given only to individuals who are seropositive for dengue antibodies.
Source: The Lancet Infectious Diseases - Category: Infectious Diseases Authors: Ma íra Aguiar, Nico Stollenwerk Tags: Correspondence Source Type: research